Xiao Hu

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients

I. Nestorov, A. Deykin, Yaming Hang, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

I. Nestorov, Yue Cui, A. Deykin, 2017, Journal of clinical pharmacology.

In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a

I. Nestorov, D. Baker, M. Subramanyam, 2011, Journal of Pharmacology and Experimental Therapeutics.

In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon (cid:1) -1a

I. Nestorov, D. Baker, M. Subramanyam, 2011 .

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function

I. Nestorov, T. Marbury, A. Seddighzadeh, 2014, Journal of clinical pharmacology.

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects

I. Nestorov, K. Dawson, B. Werneburg, 2016, British journal of clinical pharmacology.

A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

I. Nestorov, D. Baker, M. Rogge, 2012, Journal of clinical pharmacology.

Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.

D. Baker, N. Pathan, D. Lindner, 2017, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.

I. Nestorov, D. Baker, M. Panzara, 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis - Peginterferon Beta-1a, Daclizumab Beta, Natalizumab

I. Nestorov, Yaming Hang, Lei Diao, 2019, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases.

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients

I. Nestorov, A. Deykin, Yaming Hang, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study

I. Nestorov, Yue Cui, A. Deykin, 2015, British journal of clinical pharmacology.

PEGylated Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Normal or Impaired Renal Function (P06.165)

A. Seddighzadeh, Xiao Hu, Larisa Miller, 2012 .